UX003: Clinical Trials

2 trials of UX003, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2

Follow UX003: new trials by email Literature Review of UX003 trials Research Report on UX003

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)
UX003 - Sly Syndrome, MPS VII
Phase 3CompletedUltragenyx Pharmaceutical Inc122015-11-102020-07-30
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
UX003, Placebo - MPS 7, Sly Syndrome
Phase 3CompletedUltragenyx Pharmaceutical Inc122014-12-012020-07-30

Conditions studied

Lysosomal Storage Diseases (2)  ·  Metabolic Diseases (2)  ·  Mucopolysaccharidoses (2)  ·  Mucopolysaccharidosis VII (2)  ·  Rare Diseases (2)

Sponsors

Ultragenyx Pharmaceutical Inc (2)

Countries

United States (2)  ·  Brazil (1)  ·  Mexico (1)  ·  Portugal (1)

Top investigators

Chester Whitley, MD (1)  ·  Mislen Bauer, MD (1)  ·  Paul Harmatz, MD (1)  ·  Raymond Wang, MD (1)

Results publications

PMID 32063397, PMID 33874971, PMID 37415957, PMID 29478819, PMID 30467742

NIH funding

2015 (1)